Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era

Area of Science:

• Immunology
• Neurology
• Vaccinology

Background:

• Multiple sclerosis (MS) patients are susceptible to infections, potentially worsening symptoms and causing relapses.
• Vaccination is vital for preventing infections by stimulating immune responses.
• The emergence of COVID-19 vaccines necessitates understanding their impact on MS patients undergoing disease-modifying therapies (DMTs).

Purpose of the Study:

• To review immune responses to vaccinations in MS patients.
• To assess the safety and importance of COVID-19 vaccination for individuals with MS.
• To inform decisions on COVID-19 vaccination in conjunction with MS DMTs.

Main Methods:

• Review of immunological studies on vaccine responses in MS.
• Analysis of how different classes of MS DMTs may influence immune reactions to vaccines.
• Evaluation of current COVID-19 vaccine data and expert consensus.

Main Results:

• Effective vaccination relies on coordinated T and B lymphocyte interactions for immunological memory and antibody production.
• Certain DMTs (e.g., type 1 interferons, glatiramer acetate) may not significantly impair vaccine responses.
• Other DMTs (e.g., S1P receptor modulators, alemtuzumab, anti-CD20 therapies) can attenuate immune responses to vaccines.

Conclusions:

• While specific COVID-19 vaccine data in MS patients is pending, understanding immune responses is critical.
• Vaccination decisions for MS patients should be individualized, considering disease severity, infection risk, and DMT effects.
• Expert consensus and available data support the importance of COVID-19 vaccination for people with MS.